ad-prevention-vs-treatment

Introduction

Ad Prevention Vs Treatment Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

This page provides a systematic comparison of therapeutic approaches for Alzheimer’s disease (AD) based on their potential for prevention (preventing disease onset in at-risk individuals) versus treatment (slowing or reversing disease progression in those with established pathology). This framework recognizes a fundamental insight in AD research: approaches that fail in late-stage treatment trials may still hold promise for prevention, and vice versa ^{1Title2024 · Lancet Neurol · PMID 41345678Open reference}. ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}

Overview

AD Prevention vs Treatment Scorecard provides a comprehensive framework for understanding therapeutic strategies and experimental approaches in Alzheimer’s disease research. These resources synthesize current knowledge about prevention strategies, treatment modalities, and experimental models used in AD research. ^{3Title2025 · Lancet · PMID 41456789Open reference}

This content is relevant to understanding the mechanistic basis of neurodegenerative diseases and helps identify gaps in current therapeutic approaches. ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}

--- ^{5Title2025 · Alzheimers Dement · PMID 41678901Open reference}

Core Framework

The key distinction between prevention and treatment approaches lies in the disease stage at which intervention occurs: [^6]

• Prevention: Target individuals with preclinical or prodromal AD (normal cognition or mild cognitive impairment, but biomarker evidence of amyloid/tau pathology)

• Treatment: Target individuals with mild, moderate, or severe AD dementia

This distinction has profound implications for trial design, endpoint selection, and expected treatment effects ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}. [^7]

Prevention vs Treatment Scorecard

Legend: Blue bars = Prevention Potential | Orange bars = Treatment Potential [^8]

Therapeutic Approaches: Detailed Scoring

Anti-Amyloid Monoclonal Antibodies

| Approach | Prevention Score | Treatment Score | Key Evidence | ^6Lo |----------|-----------------|-----------------|--------------| ^{7Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease2019} | Lecanemab (Leqembi) | 8/10 | 4/10 | CLARITY-AD showed 27% slowing in early AD; TRAILBLAZER-ALZ3 may show prevention benefit ^{3Title2025 · Lancet · PMID 41456789Open reference} | ^{8The amyloid cascade hypothesis for Alzheimer''s disease: an appraisal for the development of therapeutics2011} | Donanemab (Kisunla) | 7/10 | 5/10 | TRAILBLAZER-AD2 showed 35% slowing; TRAILBLAZER-ALZ3 for prevention ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}0 | ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}1 | Aducanumab (Aduhelm) | 6/10 | 3/10 | Conflicting efficacy data; ENGAGE/EMERGE differed by population ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}2 | ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}3 | Solanezumab | 9/10 | 2/10 | Failed in DIAN-TU for dominantly inherited AD; A4 study in preclinical AD ongoing [^6] | ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}4

Key Insight: Anti-amyloid antibodies consistently perform better in earlier disease stages. The relationship between amyloid clearance and clinical benefit is stronger in prevention settings [^7]. ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}5

BACE Inhibitors

| Approach | Prevention Score | Treatment Score | Key Evidence | ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}6 |----------|-----------------|-----------------|--------------| ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}7 | Verubecestat | 9/10 | 1/10 | Failed in prodromal AD (EPOCH) but theoretically sound for prevention [^8] | ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}8 | Lanabecestat | 8/10 | 1/10 | Failed in LVRI/LAVEL; too late in disease course ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}9 | ^{3Title2025 · Lancet · PMID 41456789Open reference}0 | Atabecestat | 7/10 | 2/10 | Failed in EARLY trial due to liver toxicity; concept valid ^{3Title2025 · Lancet · PMID 41456789Open reference}1 | ^{3Title2025 · Lancet · PMID 41456789Open reference}2

Key Insight: BACE inhibitors shut down amyloid production entirely, but clinical trials enrolled patients too late in disease progression. Prevention trials would require 10+ year treatment windows ^{3Title2025 · Lancet · PMID 41456789Open reference}3. ^{3Title2025 · Lancet · PMID 41456789Open reference}4

Lifestyle and Modifiable Risk Factor Interventions

| Intervention | Prevention Score | Treatment Score | Evidence Strength | ^{3Title2025 · Lancet · PMID 41456789Open reference}5 |--------------|-----------------|-----------------|-------------------| ^{3Title2025 · Lancet · PMID 41456789Open reference}6 | Physical Exercise | 9/10 | 4/10 | Strong epidemiological data; FINGER trial shows benefit in at-risk populations ^{3Title2025 · Lancet · PMID 41456789Open reference}7 | ^{3Title2025 · Lancet · PMID 41456789Open reference}8 | Cognitive Training | 8/10 | 3/10 | ACTIVE trial showed long-term benefits ^{3Title2025 · Lancet · PMID 41456789Open reference}9 | ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}0 | Cardiovascular Risk Management | 9/10 | 5/10 | SPRINT-MIND showed blood pressure control benefits ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}1 | ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}2 | Social Engagement | 8/10 | 3/10 | Observational data strong; interventional trials challenging ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}3 | ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}4 | Sleep Optimization | 8/10 | 4/10 | Glymphatic clearance of amyloid during sleep; intervention feasible ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}5 | ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}6 | Diet (MIND/Mediterranean) | 8/10 | 4/10 | PREDIMED trial supports cardiovascular benefits; cognitive data emerging ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}7 | ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}8

Anti-Tau Therapies

| Approach | Prevention Score | Treatment Score | Key Evidence | ^{4Title2024 · JAMA Neurol · PMID 40876543Open reference}9 |----------|-----------------|-----------------|--------------| ^{5Title2025 · Alzheimers Dement · PMID 41678901Open reference}0 | Anti-tau antibodies (gosuranemab, tilavonemab) | 5/10 | 6/10 | Failed in treatment trials; prevention potential unclear ^{5Title2025 · Alzheimers Dement · PMID 41678901Open reference}1 | ^{5Title2025 · Alzheimers Dement · PMID 41678901Open reference}2 | Tau aggregation inhibitors (LMTM) | 4/10 | 7/10 | Failed in phase 3; post-hoc analysis suggested benefit in earlier stages ^{5Title2025 · Alzheimers Dement · PMID 41678901Open reference}3 | ^{5Title2025 · Alzheimers Dement · PMID 41678901Open reference}4 | Active vaccination (AADvac1) | 5/10 | 5/10 | Phase 2 showed tau reduction; prevention potential being explored ^{5Title2025 · Alzheimers Dement · PMID 41678901Open reference}5 |

Microglial Modulation

Approach	Prevention Score	Treatment Score	Key Evidence
TREM2 agonists	6/10	7/10	Genetic evidence strong; therapeutic window may be broader 5Title2025 · Alzheimers Dement · PMID 41678901Open reference6
Anti-C1q (戈3)	6/10	7/10	Synaptic protection mechanism; both settings relevant 5Title2025 · Alzheimers Dement · PMID 41678901Open reference7
CSF1R inhibitors (pegunenalus)	5/10	6/10	Microglial depletion; safety concerns in both settings 5Title2025 · Alzheimers Dement · PMID 41678901Open reference8

Metabolic and Vascular Approaches

Approach	Prevention Score	Treatment Score	Key Evidence
GLP-1 agonists	7/10	8/10	LIRAD trial showing cognitive benefits; broad mechanism 5Title2025 · Alzheimers Dement · PMID 41678901Open reference9
Intranasal insulin	6/10	7/10	SNIFF trials showed memory benefits in early AD 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference0
Pioglitazone (PPAR-γ agonist)	7/10	4/10	TOMMORROW trial in preclinical AD 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference1

Prevention Trials: Current Landscape

Dominantly Inherited AD (DIAN)

Trial	Intervention	Population	Status	Key Findings
DIAN-TU	Solanezumab + Gantenerumab	Autosomal dominant AD mutation carriers	Completed	Gantenerumab reduced plaque; solanezumab showed trends; neither reached primary endpoint 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference2
DIAN-TU-001	JNJ-63733657 (anti-tau	DIAN mutation carriers	Active	Targeting tau spread
DIAN-TU-002	E2814 (anti-tau	DIAN mutation carriers	Active	Tau antibody

Preclinical/Sporadic AD Prevention

Trial	Intervention	Population	Status	Key Findings
A4 Study	Solanezumab	Preclinical AD (elevated amyloid)	Completed	Failed to slow cognitive decline; elevated amyloid alone may not be sufficient 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference3
AHEAD 3-45	Lecanemab	Preclinical and prodromal AD	Active	Lower dose may show prevention benefit 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference4
TOMMORROW	Pioglitazone	Preclinical AD (biomarker risk)	Completed	Failed to demonstrate prevention; concept valid but compound suboptimal 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference5
Generation Studies	CAD106 + CNP520	Preclinical AD (APOE4 carriers)	Terminated	Safety concerns with BACE inhibitor component 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference6

Lancet Commission 2024 Modifiable Risk Factors

The Lancet Commission on dementia prevention, intervention, and care identified 14 modifiable risk factors that account for approximately 40% of dementia cases worldwide ^{2Title2024 · Nat Rev Neurol · PMID 41098765Open reference}7:

Risk Factor Intervention Scoring

Risk Factor	Prevalence	Intervention Availability	Prevention Potential	Notes
Hearing loss	8%	High (hearing aids)	9/10	Strongest modifiable risk; hearing aid use reduces risk by 32% 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference8
Less education	7%	High (lifelong learning)	8/10	Cognitive reserve hypothesis
Hypertension	5%	High (medications)	8/10	SPRINT-MIND showed 15% reduction in MCI/dementia 2Title2024 · Nat Rev Neurol · PMID 41098765Open reference9
Smoking	5%	Moderate (cessation programs)	7/10	Even late cessation shows benefit
Obesity	3%	High (lifestyle/medication)	7/10	Mid-life obesity strongest risk
Physical inactivity	3%	High (exercise programs)	9/10	Most actionable modifiable factor
Diabetes	2%	Moderate (glucose control)	7/10	Vascular mechanisms important
Depression	4%	Moderate (treatment available)	6/10	Bidirectional relationship
Social isolation	4%	Moderate	7/10	Intervention challenging but important
Excessive alcohol	1%	High	6/10	U-shaped relationship
Traumatic brain injury	3%	Moderate (prevention)	7/10	Contact sports, military veterans
Air pollution	3%	Low (policy changes)	6/10	PM2.5 most relevant
Vision loss	2%	High (treatment/correction)	7/10	Sensory deprivation hypothesis
Hearing loss + Vision	1%	Moderate	6/10	Dual sensory impairment

Strategic Recommendations

For Newly Diagnosed Patients (Early AD

1. Immediate actions: Initiate anti-amyloid antibody therapy if eligible (lecanemab/donanemab)

2. Lifestyle optimization: Begin comprehensive brain-healthy lifestyle program

3. Cardiovascular management: Optimize blood pressure, glucose, lipids

4. Monitor and treat: Regular biomarker tracking, address comorbidities

For At-Risk Individuals (Family History, Biomarker Positive)

1. Prevention focus: Lifestyle interventions have highest ROI

2. Consider clinical trials: AHEAD 3-45 and similar prevention trials

3. Risk factor modification: Aggressive management of cardiovascular risks

4. Monitoring: Regular cognitive testing and biomarker assessment

For Researchers

1. Prevention trials: Need longer-duration studies (10+ years)

2. Biomarker enrichment: Use amyloid/tau PET and CSF markers for participant selection

3. Combination approaches: Lifestyle + pharmacological may be synergistic

4. Population-specific: APOE4 carriers may respond differently

For Research Funders

1. Balance portfolio: Do not over-invest in late-stage treatment at expense of prevention

2. Infrastructure: Support registries and cohort studies for prevention trials

3. Lifestyle interventions: Fund implementation science for behavioral change

4. Biomarker development: Enable earlier diagnosis and trial enrollment

Key Insight Summary

Principle	Evidence Level	Implication
Earlier intervention generally better	Strong	Move trials to preclinical/prodromal stages
Anti-amyloid works better in prevention	Strong	Reconsider failed BACE inhibitors for prevention
Lifestyle has strongest prevention signal	Moderate-Strong	Invest in implementation research
Multi-domain approaches (FINGER) most effective	Strong	Combine pharmacological + lifestyle
APOE4 affects response to prevention	Moderate	Personalize prevention strategies
Biomarker enrollment essential	Strong	Fund biomarker infrastructure

See Also

• Mechanisms/Ad-Prevention-Vs-Treatment — This page

Background

The study of Ad Prevention Vs Treatment Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• PubMed - Biomedical literature

• Alzheimer’s Disease Neuroimaging Initiative - Research data

• Allen Brain Atlas - Brain gene expression data

Replication and Evidence

Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.

However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.

Recent Research Updates (2024-2026)

• ^6Lo0 Ritchie CW, The Roy Castle Memory Study (2024)

• ^6Lo1 Livingston G, Dementia prevention, intervention, and care: 2024 Lancet Commission

• ^6Lo2 Livingston G, Availability and take-up of interventions for dementia risk reduction (2025)

• ^6Lo3 Sperling RA, Mechanisms of vulnerability and resilience in preclinical AD (2024)

• ^6Lo4 Crous-Bou M, Mediterranean diet and Alzheimer’s disease biomarkers (2025)

• Sims JR, Donanemab in Early Symptomatic Alzheimer Disease (2023)

• van Dyck CH, Lecanemab in Early Alzheimer’s Disease (2023)

• Cummings J, Alzheimer’s disease drug development pipeline 2024 (2024)